Loading
A phase 2/3 trial testing Uliledlimab in non-small-cell lung cancer, active and no longer recruiting.
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06984588, led by TJ Biopharma, and active but no longer recruiting on the registry. Official title: A Phase II/III, Randomised, Multicenter, Open-Label Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer. Planned enrolment is 450 participants (estimated). The study started in 2024-03-28 and primary completion is expected in 2028-08-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TJ Biopharma, Uliledlimab, CD73 / adenosine axis, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/